PulseAugur
EN
LIVE 14:08:14

CAR T-cell therapy shows remarkable 10-year success in lymphoma patients

By PulseAugur Editorial · [1 sources] ·

A decade-long study tracking patients with aggressive blood cancers has revealed that CAR T-cell therapy can lead to long-term remission for a significant portion of individuals. Approximately one-third of patients with aggressive non-Hodgkin lymphoma remained cancer-free ten years after a single CAR T infusion, while nearly half of those with a slower-growing form achieved similar outcomes. This breakthrough offers hope for a potential cure, moving beyond traditional treatments towards living, programmable therapies that could redefine cancer care. AI

RANK_REASON Research findings on the long-term efficacy of a medical therapy. [lever_c_demoted from research: ic=1 ai=0.1]

Read on Forbes — Innovation →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

CAR T-cell therapy shows remarkable 10-year success in lymphoma patients

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Research findings on the long-term efficacy of a medical therapy. [lever_c_demoted from research: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
48 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Forbes — Innovation TIER_1 English(EN) · William A. Haseltine, Contributor ·

    The Remarkable Success Of CAR T For Lymphoma Ten Years On

    Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas cancer-free, pointing toward true long-term cures.

RELATED ENTITIES

RELATED TOPICS